Addressing irAEs Limits Interruption or Discontinuation in HCC
In a retrospective study in patients with hepatocellular carcinoma, 40% of patients developed irAEs after receiving the first and second doses of immunotherapy.
In a retrospective study in patients with hepatocellular carcinoma, 40% of patients developed irAEs after receiving the first and second doses of immunotherapy.
In today’s episode, we bring you key highlights from ESMO Breast 2024, diving into important discussions surrounding the latest research…
Bladder Cancer statistics
CSPs increase thrombin generation in recipients but fail to show integrin activation.Procoagulant function of CSPs can be predicted by lyso-platelet activa
Findings from a phase 1b/2 study support the continued development of palazestrant plus ribociclib for patients with estrogen receptor-positive/HER2-negative metastatic breast cancer.
CD33/CD123 NANOBODY TCE kills single and double-positive cells, outperforming single-targeting TCE in a subset of AML samples.CD33/CD123-TCE efficiently ki
0:15 – Meeting Begins3:10 – Opening Keynote from Namandjé Bumpus, U.S. FDA and Peter Marks, CBER, U.S. FDA28:42 – The Evolution of Cell and Gene…
Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Nature Cancer – Rezvan and colleagues profile the infusion product from individuals with DLBCL treated with CAR T cells and integrate functional profiling by timelapse…
Nature Cancer – Zeiser and colleagues show that CAR T cell therapy results in upregulation of the TGFβ-activated kinase-1 (TAK1)–NF-κB–p38 MAPK pathway in microglia, causing…
A study suggests that a novel CAR T-cell therapy could be a curative treatment for some patients with chronic lymphocytic leukemia, with 25% of responders…